| Title |
Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations
|
|---|---|
| Published in |
Molecular Cancer Therapeutics, October 2021
|
| DOI | 10.1158/1535-7163.mct-21-0632 |
| Pubmed ID | |
| Authors |
Brion W. Murray, Evan Rogers, Dayong Zhai, Wei Deng, Xi Chen, Paul A. Sprengeler, Xin Zhang, Armin Graber, Siegfried H. Reich, Shanna Stopatschinskaja, Benjamin Solomon, Benjamin Besse, Alexander Drilon |
X Demographics
The data shown below were collected from the profiles of 12 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 25% |
| Italy | 1 | 8% |
| Colombia | 1 | 8% |
| Mexico | 1 | 8% |
| Unknown | 6 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 50% |
| Scientists | 3 | 25% |
| Science communicators (journalists, bloggers, editors) | 2 | 17% |
| Practitioners (doctors, other healthcare professionals) | 1 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 24 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 25% |
| Other | 3 | 13% |
| Student > Doctoral Student | 2 | 8% |
| Student > Master | 1 | 4% |
| Professor | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 11 | 46% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 21% |
| Biochemistry, Genetics and Molecular Biology | 4 | 17% |
| Chemistry | 2 | 8% |
| Agricultural and Biological Sciences | 1 | 4% |
| Unknown | 12 | 50% |
Attention Score in Context
This research output has an Altmetric Attention Score of 110. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 March 2024.
All research outputs
#385,459
of 25,589,756 outputs
Outputs from Molecular Cancer Therapeutics
#39
of 4,075 outputs
Outputs of similar age
#9,711
of 437,615 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#2
of 33 outputs
Altmetric has tracked 25,589,756 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,075 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.9. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 437,615 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 33 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.